TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30658377

Group type: EXPERIMENTAL
Intervention: Stabilized chlorine dioxide mouthwash (0.1%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 50
Study: 26679830

Group type: EXPERIMENTAL
Intervention: AUD$30 cash following receipt of doses two and three (incentive condition)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Standard care (control condition)
Number of subjects: 139
Study: 24632109

Group type: EXPERIMENTAL
Intervention: family‐based treatment
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: individual adolescent supportive psychotherapy
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: weight gain
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: longer duration of illness, greater eating disorder pathology, binge‐eating/purging subtype
Number of subjects: 121
Study: 23338252

Group type: EXPERIMENTAL
Intervention: Selective COX‐2 inhibitor
Number of subjects: 30

Group type: COMPARATOR
Intervention: Steroidal anti-inflammatory drug
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 20927421

Group type: COMPARATOR
Intervention: One-stage putty-wash impressions
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Monophase impressions
Number of subjects: 48

Group type: COMPARATOR
Intervention: Two-stage putty-wash impressions
Number of subjects: 48
Study: 18375714

Group type: EXPERIMENTAL
Intervention: Proportional assisted ventilation (PAV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Sham ventilation
Number of subjects: 9
Study: 15847627

Group type: EXPERIMENTAL
Intervention: Harm minimization intervention (eight 1-hour lessons over 2 years, quitting support from school nurses, enactment of supportive policies)
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Harm minimization intervention
Number of subjects: 4000

Group type: COMPARATOR
Intervention: Standard abstinence-based programme
Number of subjects: 4000
Study: 12419715

Group type: EXPERIMENTAL
Intervention: Three minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ten minutes of supramaximal stimulation (0.1 Hz, 20 mA) before mivacurium 0.2 mg.kg(‐1)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Three minutes of supramaximal stimulation measured by AMG
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ten minutes of supramaximal stimulation measured by AMG
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison of PMG and AMG
Number of subjects: 20
Study: 11153926

Group type: EXPERIMENTAL
Intervention: Chelating agent (DMPS)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 9195520

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 35

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 35

Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 35

Group type: COMPARATOR
Intervention: Sulindac
Number of subjects: 35
Study: 8244121

Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 289

Group type: COMPARATOR
Intervention: Ranitidine 300 mg
Number of subjects: 289
Study: 4033539

Group type: EXPERIMENTAL
Intervention: Prednisone (1.2 mg/kg/day for 70 days)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Prednisone with alkylating agents
Number of subjects: 32

Group type: COMPARATOR
Intervention: Alkylating agent alone
Number of subjects: 32
Study: 30390523

Group type: EXPERIMENTAL
Intervention: Androsta‐4,16,‐dien‐3‐one (androstadienone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Estra‐1,3,5(10),16‐tetraen‐3‐ol (estratetraenol)
Number of subjects: 0
Study: 29720379

Group type: EXPERIMENTAL
Intervention: Trigger point dry needling (TrP‐DN)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo needling
Number of subjects: 56

Group type: COMPARATOR
Intervention: No treatment (untreated control group)
Number of subjects: 56
Study: 27676085

Group type: EXPERIMENTAL
Intervention: Oral extended-release calcifediol (30 or 60 µg) once daily at bedtime for 26 weeks
Number of subjects: 429

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study: 24030517

Group type: EXPERIMENTAL
Intervention: Commercial programme (CP)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 772
Study: 22264653

Group type: EXPERIMENTAL
Intervention: Olive oil + exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Butter + no exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Olive oil + no exercise
Number of subjects: 9

Group type: COMPARATOR
Intervention: Butter + exercise
Number of subjects: 9
Study: 20141260

Group type: EXPERIMENTAL
Intervention: Attention to nonthreatening words and text while ignoring worry-related material
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mixed-attention control condition
Number of subjects: 0
Study: 18277062

Group type: EXPERIMENTAL
Intervention: Immediate distant healing for 6 months
Number of subjects: 409

Group type: COMPARATOR
Intervention: Deferred distant healing (waiting for 6 months)
Number of subjects: 409

Group type: EXPERIMENTAL
Intervention: Blinding (unblinded patients)
Number of subjects: 409
Study: 15886057

Group type: EXPERIMENTAL
Intervention: Cardibra (treatment group)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Regular bra (control group)
Number of subjects: 20
Study: 12642846

Group type: EXPERIMENTAL
Intervention: Desloratadine 5 mg once daily
Number of subjects: 676

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 676
Study: 10384914

Group type: EXPERIMENTAL
Intervention: Intrademal injections of 100 microg/ml compound 48/80
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1% capsaicin cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (bullous pemphigoid, herpes zoster, insect bullous eruption)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wheal reaction induced immediately before suction blistering
Number of subjects: 0
Study: 8882821

Group type: EXPERIMENTAL
Intervention: High-speed rotational angioplasty after primary guidewire recanalization
Number of subjects: 124

Group type: COMPARATOR
Intervention: Sequential PTCA
Number of subjects: 124
Study: 28685934

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/d for 6 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: RAAS inhibition
Number of subjects: 26
Study: 27496788

Group type: EXPERIMENTAL
Intervention: Wholegrain pasta (WGP)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Refined grain pasta (RGP)
Number of subjects: 16
Study: 24990161

Group type: EXPERIMENTAL
Intervention: Rikkunshito (RKT) combined with rabeprazole (RPZ) 10 mg/q.d. for 8 weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo (PL) combined with rabeprazole (RPZ) 10 mg/q.d. for 8 weeks
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Rikkunshito (RKT)
Number of subjects: 95
Study: 22883036

Group type: EXPERIMENTAL
Intervention: Morphine infusion (loading dose 100 µg/kg followed by continuous infusion 10 µg/(kg·h) for 70.05 ± 29.05 h)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Morphine infusion
Number of subjects: 46

Group type: COMPARATOR
Intervention: 5% glucose infusion (control group)
Number of subjects: 46
Study: 21605286

Group type: EXPERIMENTAL
Intervention: full-mouth disinfection
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: full-mouth scaling and root planing
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: scaling and root planing within 7 days
Number of subjects: 54

Group type: COMPARATOR
Intervention: initial carious lesions
Number of subjects: 54

Group type: COMPARATOR
Intervention: sound surfaces
Number of subjects: 54
Study: 17398372

Group type: EXPERIMENTAL
Intervention: 40 mg simvastatin daily
Number of subjects: 20536

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 20536
Study: 15642701

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 10
Study: 12095189

Group type: EXPERIMENTAL
Intervention: High narcissism with low self-concept clarity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Less narcissistic individuals with high self-concept clarity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anger and depression
Number of subjects: 0
Study: 10786531

Group type: EXPERIMENTAL
Intervention: Education programme on how to use and take care of a PIV; details on dosage and duration not available.
Number of subjects: 36

Group type: COMPARATOR
Intervention: Current routines followed by nurses in the control group; details on dosage and duration not available.
Number of subjects: 36
Study: 8647062

Group type: EXPERIMENTAL
Intervention: Nutrilon Pept
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pepti Junior
Number of subjects: 79
Study: 1972313

Group type: EXPERIMENTAL
Intervention: Aldactazine alone (altizide + spironolactone, 2 tablets per day)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Aldactazine plus a conventional antihypertensive agent (1 or 2 tablets per day)
Number of subjects: 780
Study: 116856

Group type: EXPERIMENTAL
Intervention: Clonidine (CL) 2 x 75 microgram/day for 2 weeks
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine (CL)
Number of subjects: 60
Study: 31830014

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) injection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 0
Study: 28692531

Group type: EXPERIMENTAL
Intervention: EFV-based ART
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: NVP-based ART
Number of subjects: 60

Group type: COMPARATOR
Intervention: ART-naive
Number of subjects: 60
Study: 25517202

Group type: EXPERIMENTAL
Intervention: Caffeine chewing gum (3-4 mg · kg(‐1))
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo chewing gum
Number of subjects: 20
Study: 23418316

Group type: EXPERIMENTAL
Intervention: Intrajejunal taurocholic acid (TCA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 10
Study: 21078418

Group type: EXPERIMENTAL
Intervention: Tai Chi Group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 0
Study: 19348407

Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Empathic attitude of the nurse
Number of subjects: 0
Study: 16432471

Group type: EXPERIMENTAL
Intervention: Contact lens wear
Number of subjects: 484

Group type: COMPARATOR
Intervention: Spectacle wear
Number of subjects: 484
Study: 15319562

Group type: EXPERIMENTAL
Intervention: Manual lymph drainage massage (MLD) in combination with multi-layered compression bandaging (CB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Compression bandaging (CB) alone
Number of subjects: 50
Study: 10922420

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg bolus intravenous injection followed by 8 mg per hour infusion for 72 hours, then 20 mg orally per day for 8 weeks)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo (same treatment protocol as omeprazole but without the active drug)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Omeprazole
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 9314091

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg daily for 7 days
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Propafenone 300 mg per os twice a day
Number of subjects: 85
Study: 7870968

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine (0.25 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine (0.5 mg/kg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intravenous meperidine (1.0 mg/kg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 10
Study: 3024879

Group type: EXPERIMENTAL
Intervention: Atropine (1 mg i.m.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: GHRH (1 microgram/kg i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: TRH (300 micrograms i.v.) plus LHRH (100 micrograms i.v.) plus CRH (1 microgram/kg i.v.)
Number of subjects: 10
Study: 31853550

Group type: EXPERIMENTAL
Intervention: Intravenous hydrocortisone replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low glucocorticoid replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium glucocorticoid replacement
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High glucocorticoid replacement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Addison's disease patients
Number of subjects: 0
Study: 29987079

Group type: EXPERIMENTAL
Intervention: Access to the illness-focused interactive booklet
Number of subjects: 25355

Group type: COMPARATOR
Intervention: Usual care (no access to the booklet)
Number of subjects: 25355
Study: 26852745

Group type: EXPERIMENTAL
Intervention: 1000 mg levofloxacin
Number of subjects: 12
Study: 26553692

Group type: EXPERIMENTAL
Intervention: YF vaccine coadministered with PsA‐TT and measles vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 24078364

Group type: EXPERIMENTAL
Intervention: Culturally competent diabetes care training course
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 90
Study: 20065174

Group type: EXPERIMENTAL
Intervention: Preoperative CRT with capecitabine, oxaliplatin, and concurrent radiation followed by surgery and four cycles of postoperative adjuvant capecitabine and oxaliplatin (CAPOX)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Induction CAPOX followed by CRT and surgery
Number of subjects: 108

Group type: COMPARATOR
Intervention: Postoperative adjuvant CAPOX
Number of subjects: 108
Study: 19052197

Group type: EXPERIMENTAL
Intervention: Placebo treatment for 8 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Homozygous for the long allele of the 5-HTTLPR or the G variant of the TPH2 G-703T polymorphism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPH2 polymorphism
Number of subjects: 0
Study: 15975497

Group type: EXPERIMENTAL
Intervention: Low protein/high carbohydrate shake (17% protein, 75% carbohydrate, 8% fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High protein/low carbohydrate shake (62% protein, 28% carbohydrate, 10% fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: 100% protein shake
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Comparison of low protein/high carbohydrate shake and high protein/low carbohydrate shake
Number of subjects: 8

Group type: COMPARATOR
Intervention: Comparison of shakes with 100% protein shake
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Respiratory exchange ratio over 3 h
Number of subjects: 8
Study: 12357013

Group type: EXPERIMENTAL
Intervention: Computerised prompt
Number of subjects: 431

Group type: COMPARATOR
Intervention: Control group (no prompt)
Number of subjects: 431
Study: 10425293

Group type: EXPERIMENTAL
Intervention: Thymidine phosphorylase (dThdPase) activity measured by liquid chromatography
Number of subjects: 42
Study: 7483997

Group type: EXPERIMENTAL
Intervention: AutoPap 300 QC System
Number of subjects: 3487

Group type: COMPARATOR
Intervention: Cytotechnologist rescreening
Number of subjects: 3487
Study: 2258519

Group type: EXPERIMENTAL
Intervention: In-patient education and telephone monitoring during convalescence
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Self-efficacy expectations summed for all physical activities at 8 weeks
Number of subjects: 149
Study: 6263072

Group type: EXPERIMENTAL
Intervention: Oat-bran diet (100 g of oat bran)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 8
Study: 29605574

Group type: EXPERIMENTAL
Intervention: Cinnamon supplementation (500 mg capsules twice daily for 3 months)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (500 mg capsules twice daily for 3 months)
Number of subjects: 140
Study: 31074791

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (194/206mg)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan (194/206mg) combined with sitagliptin (2x100mg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sitagliptin (2x100mg) alone
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (standardized meal without sacubitril/valsartan)
Number of subjects: 19
Study: 28261679

Group type: COMPARATOR
Intervention: ESWL only (Group 1)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Stenting followed by ESWL (Group 2)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Stenting for 1 week followed by ESWL (Group 3)
Number of subjects: 95
Study: 26421695

Group type: EXPERIMENTAL
Intervention: Resistance exercise program
Number of subjects: 0
Study: 23839228

Group type: EXPERIMENTAL
Intervention: Computed virtual chromoendoscopy (group B)
Number of subjects: 78

Group type: COMPARATOR
Intervention: High-definition white light endoscopy (group A)
Number of subjects: 78
Study: 21231791

Group type: EXPERIMENTAL
Intervention: Multimodal intervention including an interview about rehabilitation needs with a rehabilitation coordinator, information from the hospital to the GP about individual needs for rehabilitation, and an incentive for the GP to contact the patient.
Number of subjects: 955

Group type: COMPARATOR
Intervention: Usual procedures (control group)
Number of subjects: 955
Study: 18328518

Group type: EXPERIMENTAL
Intervention: Chlorproguanil/dapsone + artesunate (CD+A)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Amodiaquine+sulfadoxine/pyrimethamine (AQ+SP)
Number of subjects: 800
Study: 16426473

Group type: EXPERIMENTAL
Intervention: Single-use scented intersurgical face mask
Number of subjects: 48

Group type: COMPARATOR
Intervention: Single-use cushioned 7,000 series Air Safety Ltd. face mask
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reusable silicone Laerdal face mask
Number of subjects: 48

Group type: COMPARATOR
Intervention: Reusable anatomical intersurgical face mask
Number of subjects: 48
Study: 12616104

Group type: COMPARATOR
Intervention: IL-2 alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IL-2 + GM-CSF (125 mcg/m)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IL-2 + GM-CSF (250 mcg/m)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: IL-2 + GM-CSF (all doses)
Number of subjects: 21
Study: 11775394

Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 36

Group type: COMPARATOR
Intervention: Water
Number of subjects: 36
Study: 9279225

Group type: EXPERIMENTAL
Intervention: No routine in-line suction catheter changes
Number of subjects: 521

Group type: COMPARATOR
Intervention: In-line suction catheter changes every 24 h
Number of subjects: 521

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 521
Study: 8345498

Group type: EXPERIMENTAL
Intervention: Enalapril (4 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nitrendipine (6 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (first period)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (second period)
Number of subjects: 30
Study: 3524727

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo transcutaneous nerve stimulation
Number of subjects: 25
Study: 30179971

Group type: EXPERIMENTAL
Intervention: Gold sodium thiosulfate HYD 0.075 mg/cm
Number of subjects: 255

Group type: COMPARATOR
Intervention: Gold sodium thiosulfate 0.5% pet
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Gold sodium thiosulfate HYD
Number of subjects: 255
Study: 26749163

Group type: EXPERIMENTAL
Intervention: CBCC resource pack and workshop
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: CBCC resource pack only
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Nutrition-only resource
Number of subjects: 4

Group type: COMPARATOR
Intervention: No interventions (waitlist control)
Number of subjects: 4
Study: 24906545

Group type: EXPERIMENTAL
Intervention: 10 TOCT sessions over 2 weeks (2 hours/each session) followed by a 3 months home exercise program
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no specific rehabilitation intervention)
Number of subjects: 24
Study: 22426845

Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 20409671

Group type: EXPERIMENTAL
Intervention: FTO A allele
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: BclI G/G genotype
Number of subjects: 98
Study: 18216373

Group type: EXPERIMENTAL
Intervention: Self-etching primer (SEP) - Transbond Plus
Number of subjects: 37

Group type: COMPARATOR
Intervention: Conventional method (CM) - Transbond XT
Number of subjects: 37
Study: 16172795

Group type: EXPERIMENTAL
Intervention: 24 h drainage
Number of subjects: 100

Group type: COMPARATOR
Intervention: Long-term drainage
Number of subjects: 100
Study: 12514683

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment in the ED by an advanced practice nurse and subsequent referral to community or social agency, primary care provider, and/or geriatric clinic for unmet health, social, and medical needs.
Number of subjects: 650

Group type: COMPARATOR
Intervention: Usual and customary ED care
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment in the ED
Number of subjects: 650
Study: 10795791

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (4 x 5 g creatine + 1 g glucose x d(‐1), N = 11)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo (4 x 6 g glucose x d(‐1), N = 12)
Number of subjects: 23
Study: 8677576

Group type: EXPERIMENTAL
Intervention: Single oral dose of 400 mg fleroxacin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Single intravenous (IV) dose of 400 mg fleroxacin
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Extended regimen of initial 400 mg IV dose followed by oral therapy (400 mg/day or 200 mg/day for specific patients)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (no antibiotic prophylaxis mentioned)
Number of subjects: 84
Study: 2497545

Group type: EXPERIMENTAL
Intervention: 1 mg ASA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 10 mg ASA
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 20 mg ASA
Number of subjects: 18
Study: 195201

Group type: EXPERIMENTAL
Intervention: 0.3 g butylbiguanide and 1.5 g clofibrate/day
Number of subjects: 21

Group type: COMPARATOR
Intervention: 1.5 g clofibrate/day
Number of subjects: 21